The interplay between NK cells and the PD-1/PD-L1 axis presents a strategic opportunity for overcoming resistance mechanisms, potentially unlocking more robust and sustained antitumor responses in ovarian cancer patients (77). This evidence concerns the gene CD274 and ovarian carcinoma.